gemcitabine + cisplatin + Placebo + cisplatin + cediranib + gemcitabine
Phase 2/3Completed 0 watching 0 views this week📈 Rising
65
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Biliary Tract Neoplasms
Conditions
Biliary Tract Neoplasms
Trial Timeline
Apr 1, 2011 → Sep 1, 2014
NCT ID
NCT00939848About gemcitabine + cisplatin + Placebo + cisplatin + cediranib + gemcitabine
gemcitabine + cisplatin + Placebo + cisplatin + cediranib + gemcitabine is a phase 2/3 stage product being developed by AstraZeneca for Biliary Tract Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT00939848. Target conditions include Biliary Tract Neoplasms.
Hype Score Breakdown
Clinical
22
Activity
15
Company
10
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00939848 | Phase 2/3 | Completed |
Competing Products
20 competing products in Biliary Tract Neoplasms